Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
2019 · Annals of Oncology · 504 citations
https://doi.org/10.1093/annonc/mdz117
M
Mario Silva
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
312
Papers
6.3K
Citations
40
h-index
123
i10-index
Mario Silva is an academic researcher from University of Parma. The author has contributed to research in topics: Radiomics and Machine Learning in Medical Imaging & Lung Cancer Diagnosis and Treatment & Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis. The author has an h-index of 40, co-authored 266 publications.
ORCID: 0000-0002-2538-7032Papers by this author
worksDeep Learning–based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography
2022 · American Journal of Respiratory and Critical Care Medicine · 116 citations
https://doi.org/10.1164/rccm.202112-2684oc
Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen
2016 · European Radiology · 114 citations
https://doi.org/10.1007/s00330-016-4228-3
Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial
2022 · Annals of Oncology · 97 citations
https://doi.org/10.1016/j.annonc.2022.01.008
COVID-19 pneumonia imaging follow-up: when and how? A proposition from ESTI and ESR
2021 · European Radiology · 68 citations
https://doi.org/10.1007/s00330-021-08317-7
Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis
2022 · Respirology · 58 citations
https://doi.org/10.1111/resp.14333
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat